Incytes SWOT analysis pipeline progress faces patent cliff pressure
SNDX Stock | USD 13.63 0.16 1.16% |
Slightly above 67% of Syndax Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that many traders are alarmed. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syndax |
Incytes SWOT analysis pipeline progress faces patent cliff pressure
Read at investing.com
Syndax Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
EWTX | Edgewise Therapeutics | 18.36 | ||||
MRUS | Merus BV | 4.91 | ||||
PLRX | Pliant Therapeutics | 4.74 | ||||
MLYS | Mineralys Therapeutics, | 1.56 | ||||
AVTE | Aerovate Therapeutics | 1.19 | ||||
RVMD | Revolution Medicines | 1.01 | ||||
STRO | Sutro Biopharma | 0.97 | ||||
CGEM | Cullinan Oncology | 0.43 | ||||
PCVX | Vaxcyte | 0.41 | ||||
DYN | Dyne Therapeutics | 0.23 | ||||
REPL | Replimune | 0.56 | ||||
COGT | Cogent Biosciences | 0.85 | ||||
MRSN | Mersana Therapeutics | 1.93 | ||||
CYTK | Cytokinetics | 2.53 | ||||
INZY | Inozyme Pharma | 2.65 | ||||
VRDN | Viridian Therapeutics | 3.34 | ||||
KALV | Kalvista Pharmaceuticals | 3.35 | ||||
KROS | Keros Therapeutics | 7.31 | ||||
LRMR | Larimar Therapeutics | 10.56 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.